亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial

医学 贝伐单抗 地塞米松 糖尿病性视网膜病变 眼科 析因分析 黄斑病 曲安奈德 皮质类固醇 外科 糖尿病 内科学 视网膜病变 化疗 内分泌学
作者
Hemal Mehta,Samantha Fraser‐Bell,Aaron Yeung,Anna Campain,Lyndell L. Lim,Godfrey Quin,Ian L. McAllister,Pearse A. Keane,Mark C. Gillies
出处
期刊:British Journal of Ophthalmology [BMJ]
卷期号:100 (7): 1000-1004 被引量:35
标识
DOI:10.1136/bjophthalmol-2015-307797
摘要

Objective

To report the effect of bevacizumab versus dexamethasone on hard exudates (HEX) in diabetic macular oedema (DME).

Design

Post hoc analysis of 24-month data from the Randomised clinical trial of BEVacizumab OR DEXamethasone for diabetic macular oedema (BEVORDEX) phase 2 multicentre randomised clinical trial. Eyes with centre-involving DME resistant to or unlikely to benefit from macular laser therapy were included. Eyes were randomly assigned to bevacizumab every 4 weeks or Ozurdex dexamethasone implant (DEX) every 16 weeks, both as required. The 68 eyes from 48 patients that completed 24-month follow-up were analysed. Two masked graders assessed extent and location of HEX on baseline, 12-month and 24-month foveal-centred colour fundus photographs using validated grading software.

Results

Macular HEX was present in 60% of study eyes. Of these, 21 eyes were treated with DEX and 20 eyes with bevacizumab. Both treatments led to reduction in area of macular HEX at 12 months and 24 months. There was greater regression of HEX from the foveal centre in DEX-treated eyes (median change +890 µm, IQR=1040 µm) than bevacizumab-treated eyes (median change +7.0 µm, IQR=590 µm) at 12 months (p=0.04) but the difference was no longer statistically significant (p=0.10) by 24 months (DEX +1400 µm, IQR=1590 µm; bevacizumab +20 µm, IQR=2680 µm). Reassuringly, no study eye developed HEX at the foveal centre, a visually devastating consequence of diabetic maculopathy.

Conclusions

Bevacizumab and DEX were effective in reducing area of HEX in eyes with DME. DEX provided more rapid regression of HEX from the foveal centre although bevacizumab-treated eyes started to catch up by 24 months. Distance from the foveal centre as well as total area of macular HEX should be assessed when evaluating treatments for foveal-threatening HEX.

Trial registration number

NCT01298076; Post-results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
heihei完成签到,获得积分10
24秒前
40秒前
樱桃猴子完成签到,获得积分10
43秒前
雨朵发布了新的文献求助10
45秒前
CSUST科研一哥应助LUBBY采纳,获得20
45秒前
激动的似狮完成签到,获得积分10
47秒前
雨朵完成签到,获得积分10
54秒前
懒惰扼杀激情完成签到 ,获得积分10
59秒前
Demi_Ming完成签到,获得积分10
1分钟前
1分钟前
1分钟前
动听凝安发布了新的文献求助40
1分钟前
1分钟前
小树枝发布了新的文献求助10
2分钟前
平常天佑完成签到,获得积分10
2分钟前
动听凝安发布了新的文献求助10
2分钟前
Artin完成签到,获得积分10
2分钟前
动听凝安发布了新的文献求助10
2分钟前
动听凝安完成签到,获得积分10
3分钟前
张大然完成签到 ,获得积分10
4分钟前
4分钟前
wangfaqing942完成签到 ,获得积分10
5分钟前
诚心的傲芙完成签到,获得积分10
5分钟前
5分钟前
6分钟前
Lucas应助诚心的砖头采纳,获得10
6分钟前
7分钟前
Hayat发布了新的文献求助30
7分钟前
诚心的砖头完成签到,获得积分10
7分钟前
8分钟前
春眠不觉小小酥完成签到,获得积分10
8分钟前
8分钟前
9分钟前
cosine发布了新的文献求助30
9分钟前
cosine完成签到,获得积分10
9分钟前
gszy1975完成签到,获得积分10
10分钟前
uziMOF发布了新的文献求助10
10分钟前
萧水白应助uziMOF采纳,获得10
11分钟前
xu应助Kapur采纳,获得30
11分钟前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 600
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3234564
求助须知:如何正确求助?哪些是违规求助? 2880908
关于积分的说明 8217339
捐赠科研通 2548510
什么是DOI,文献DOI怎么找? 1377807
科研通“疑难数据库(出版商)”最低求助积分说明 648006
邀请新用户注册赠送积分活动 623361